Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company, announced CEO Norbert Riedel's participation in the 'Brains of the Operation - Novel Approaches in Neuro' panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10 at 12:00 p.m. ET.

A live webcast of the discussion will be accessible on Aptinyx's 'Events and Presentations' page for 30 days post-event. The company is focused on developing therapies for nervous system disorders, utilizing proprietary synthetic small molecules to modulate NMDA receptors and enhance synaptic plasticity.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET.

A live webcast of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005144/en/

FAQ

What is Aptinyx Inc. known for?

Aptinyx Inc. is known for developing transformative therapies for nervous system disorders, particularly through proprietary NMDA receptor modulators.

When will Norbert Riedel speak at the Wedbush PacGrow Healthcare Virtual Conference?

Norbert Riedel will speak on August 10 at 12:00 p.m. ET during the conference.

Where can I watch the live webcast of the Aptinyx panel discussion?

The live webcast will be available on the 'Events and Presentations' page on Aptinyx's website.

What does Aptinyx's research focus on?

Aptinyx's research focuses on developing therapies for conditions such as chronic pain, PTSD, and cognitive impairment.

What is the stock symbol for Aptinyx?

The stock symbol for Aptinyx is APTX.